A5046115676- Pain Mechanisms and Treatments
- Musculoskeletal pain and rehabilitation
- Botulinum Toxin and Related Neurological Disorders
- Pain Management and Opioid Use
- Pain Management and Placebo Effect
- Spine and Intervertebral Disc Pathology
- Anesthesia and Pain Management
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Pediatric Pain Management Techniques
- Cancer Treatment and Pharmacology
- Myofascial pain diagnosis and treatment
- Neuropeptides and Animal Physiology
- Dental Anxiety and Anesthesia Techniques
- Pharmacological Effects of Natural Compounds
- Pharmacogenetics and Drug Metabolism
- Pain Management and Treatment
- Treatment of Major Depression
- Parkinson's Disease Mechanisms and Treatments
- Opioid Use Disorder Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Neuroscience and Neuropharmacology Research
- Biomedical and Chemical Research
- Epilepsy research and treatment
- Infrared Thermography in Medicine
- Anesthesia and Sedative Agents
Klinikum rechts der Isar
2014-2025
Technical University of Munich
2015-2025
Francis Hospital
2022
München Klinik
2015-2021
Inserm
2021
Universitätsmedizin Göttingen
2016
Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin
2013-2014
Heinrich Heine University Düsseldorf
2005-2011
Düsseldorf University Hospital
2005-2011
Medizinisches Versorgungszentrum Prof. Mathey, Prof. Schofer
2011
Objective: Nociceptive and neuropathic components both contribute to pain. Since these require different pain management strategies, correct diagnosis before during treatment is highly desirable. As low back (LBP) patients constitute an important subgroup of chronic patients, we addressed the following issues: (i) establish a simple, validated screening tool detect (NeP) in LBP (ii) determine prevalence large-scale survey, (iii) whether with NeP component suffer from worse, or different,...
Pregabalin binds with high affinity to the alpha2-delta subunit protein of voltage-gated calcium channels and, thereby, reduces release excitatory neurotransmitters. This 12-week randomised, double-blind, multicentre, placebo-controlled, parallel-group study evaluated efficacy and safety pregabalin in patients chronic postherpetic neuralgia (PHN) or painful diabetic peripheral neuropathy (DPN). Patients were randomised placebo (n=65) one two regimens: a flexible schedule 150, 300, 450, 600...
Abstract Patients with neuropathic pain are heterogeneous in etiology, pathophysiology, and clinical appearance. They exhibit a variety of pain-related sensory symptoms signs (sensory profile). Different profiles might indicate different classes neurobiological mechanisms, hence subgroups respond differently to treatment. The aim the investigation was identify large sample patients using hypothesis-free statistical methods on database 3 multinational research networks (German Research...
Patients with neuropathic pain syndromes are heterogeneous. They present a variety of sensory symptoms and qualities. The knowledge these data etiology-specific differences is important to optimize clinical trial design develop more effective drugs. This investigation uses epidemiological on the symptomatology 2100 patients painful diabetic neuropathy (DPN) postherpetic neuralgia (PHN) from cross-sectional survey (painDETECT) (1) describe characteristic differences, (2) analyse typical...
This multicentre, double-blind, parallel-group study in diabetic peripheral neuropathic pain addressed whether, patients not responding to standard doses of duloxetine or pregabalin, combining both medications is superior increasing each drug its maximum recommended dose. For initial 8-week therapy, either 60 mg/day (groups 1, 2) 300 pregabalin 3, 4) was given. Thereafter, the combination/high-dose therapy period, only nonresponders received 120 (group 1), a combination and 2, 3), 600 4)....
Abstract In a recent cluster analysis, it has been shown that patients with peripheral neuropathic pain can be grouped into 3 sensory phenotypes based on quantitative testing profiles, which are mainly characterized by either loss, intact function and mild thermal hyperalgesia and/or allodynia, or loss of detection mechanical allodynia. Here, we present an algorithm for allocation individual to these subgroups. The is nondeterministic—ie, patient sorted more than one phenotype—and separate...
Seven published, randomized, placebo-controlled clinical trials with pregabalin have shown robust efficacy for relief of neuropathic pain from DPN and PHN. An investigation the safety twice daily enrolled 395 adults painful > or = 1 year in a 12-week, double-blind, trial. Patients were randomized to placebo, 150, 300, 600 mg/day (n 96, 99, 101). Primary measure was change baseline endpoint mean score patients' diaries. Secondary measures included pain-related sleep-interference scores,...
To assess whether pseudoradicular low-back pain may be associated with subclinical sensory deficits in the distal extremity, we applied quantitative testing protocol of German Research Network on Neuropathic Pain (DFNS) 15 patients distribution. Sixteen age- and gender-matched healthy control subjects as well 12 radicular syndromes (L4-S1) were studied same protocol. Radicular was diagnosed using clinical criteria (pain radiation beyond knee, motor-, sensory-, or reflex deficits, positive...
Objectives. Patients with FM are heterogeneous. They present a variety of pain qualities, sensory abnormalities and additional comorbidities. The aim was to identify clinically distinguishable subgroups patients.
We evaluated the efficacy of pregabalin in patients with chronic lumbosacral radiculopathy. This randomized, controlled, withdrawal trial included five phases: screening (4-18 days); run-in (4-10 days) to screen out placebo responders; single-blind (28 identify double-blind randomize responders or (35 and final study medication taper (7 days). The primary endpoint was time loss response (LOR) during phase (1-point increase pain, discontinuation, rescue-medication use). In phase, 58% had 30%...
Abstract Background Patients with diabetic neuropathy (DPN) and fibromyalgia differ substantially in pathogenetic factors the spatial distribution of perceived pain. We questioned whether, despite these obvious differences, similar abnormal sensory complaints pain qualities exist both entities. hypothesized that symptoms might be associated mechanisms generation. The aims were (1) to compare epidemiological features co-morbidities (2) identify similarities differences Methods present...
Sensory profiles are heterogeneous in neuropathic pain disorders, and subgroups of patients respond differently to treatment. To further explore this, the COMBO-DN study were prospectively assessed by Neuropathic Pain Symptom Inventory (NPSI) at baseline, after initial 8-week therapy with either duloxetine or pregabalin, subsequent combination/high-dose therapy. Exploratory post hoc cluster analyses performed identify characterize potential through their scores NPSI items. In not responding...
Abstract Chronic low back pain (LBP) is a common condition, usually with the involvement of nociceptive and neuropathic components, high economic burden impact on quality life. Cebranopadol potent, first-in-class drug candidate novel mechanistic approach, combining nociceptin/orphanin FQ peptide opioid receptor agonism. We conducted first phase II, randomized, double-blind, placebo- active-controlled trial, evaluating analgesic efficacy, safety, tolerability cebranopadol in patients...
ABSTRACTObjective: Chronic back pain is characterized by a combination of neuropathic and nociceptive mechanisms generation. The prevalence the component unknown. Thus, in context an explorative study, we aimed to determine signs symptoms indicating adult patients treated orthopaedists. We also assess usefulness handheld computers (PDAs) data collection.Methods: Prospective epidemiological study 18 orthopaedic practices or centres throughout Germany. Physician patient questionnaires...
A finite number of variants in the OPRM1, COMT, MC1R, ABCB1 and CYP2D6 genes has been identified to significantly modulate effects opioids controlled homogenous settings. We analyzed imprint these opioid therapy a highly variable cohort pain patients treated outpatient units test whether genotyping may play role this clinical setting.In multicenter study conducted tertiary care centers, 352 (156 men 196 women, aged 58.5+/- 14.6 years) for 1-600 months (63.4 +/- 92.4 months) with various...
Although there is increasing knowledge of the prevalence neuropathic pain, little has been done to isolate cost especially with reference frequent complaint back pain.To estimate components in pain and associated costs.We used available epidemiological data model general adult population, combining three studies: painDETECT 1, 2, German research network (GBPRN) study, representing a total 21,047 subjects. The screening questionnaire was former two surveys assess components. Costing were...
To evaluate efficacy and safety of lacosamide compared with placebo in painful diabetic polyneuropathy.Diabetic patients at least moderate neuropathic pain were randomized to or 400 (in a slow standard titration) 600 mg/day over 6-week titration 12-week maintenance periods. Primary criterion was intra-individual change average daily Numeric Pain Rating Scale score from baseline the last 4 weeks.For primary end point, reduction numerically but not statistically greater (400 mg/day, P = 0.12;...
Axial low back pain can be considered as a syndrome with both nociceptive and neuropathic components (mixed-pain). Especially comprises therapeutic challenge in practical experience may explain why pharmacotherapy is often disappointing for the patient therapist. This survey uses epidemiological clinical data on symptomatology of 1083 patients axial from cross sectional (painDETECT). Objectives were (1) to estimate whether contributes if so what extent. (2) To detect subgroups typical...